Mechanisms of action of the sodium‐glucose cotransporter‐2 ( <scp>SGLT2)</scp> inhibitor canagliflozin on tubular inflammation and damage: A <i>post hoc mediation</i> analysis of the <scp>CANVAS</scp> trial-Reference-Cited by-同舟云学术

Mechanisms of action of the sodium‐glucose cotransporter‐2 ( SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial

Published:2022-06-28 Issue:10 Volume:24 Page:1950-1956
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Sen Taha¹^ORCID,Koshino Akihiko¹²^ORCID,Neal Bruce³^ORCID,Bijlsma Maarten J.⁴^ORCID,Arnott Clare³^ORCID,Li Jingwei³^ORCID,Hansen Michael K.⁵,Ix Joachim H.⁶⁷^ORCID,Heerspink Hiddo J. L.¹³^ORCID

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Centre Groningen Groningen The Netherlands

2. Department of Nephrology and Laboratory Medicine Kanazawa University Kanazawa Japan

3. The George Institute for Global Health UNSW Sydney Sydney New South Wales Australia

4. Unit PharmacoTherapy, Epidemiology, and Economics (PTEE), Groningen Research Institute of Pharmacy University of Groningen Groningen The Netherlands

5. Janssen Research & Development LLC Spring House Pennsylvania USA

6. Nephrology Section Veterans Affairs San Diego Healthcare System La Jolla California USA

7. Division of Nephrology‐Hypertension, Department of Medicine University of California San Diego San Diego California USA

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14779

Reference20 articles.